WHO ICTRP trial
Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor…
JPRN-UMIN000030598 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000030598 |
|---|---|
| Public title | Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study(WJOG9416L) |
| Scientific title | Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study(WJOG9416L) - DOC+RAM+PEG-G-CSF in elderly NSCLC |
| Primary sponsor | West Japan Oncology Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Non-small cell lung cancer |
| Interventions | DOC(60 mg/m2, day 1)+ RAM(10 mg/kg, day 1)&PEG-G-CSF(3.6 mg, day 2-4) every 3 weeks until progression or both DOC and RAM termination |
| Registration date | Dec 27, 2017 |
| Target size | 65 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: